100 mg
Trade Name
Amilian
Tablet
Request Type
Registration
Drug Type
Generic Drug
Approval Date
SFDA Approved Use
Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
Amisulpride also regulates secondary negative symptoms in productive state, as well as affective disorders such as depressive mood.
Amisulpride also regulates secondary negative symptoms in productive state, as well as affective disorders such as depressive mood.